Patient enrollment surpasses 90% in jaguar health's pivotal phase 3 ontarget trial of crofelemer for cancer therapy-related diarrhea

Enrollment expected to complete in mid-q2 2023 as of march 24, 2023, as previously announced, the company's cash position was approximately $15.3 million san francisco, ca / accesswire / april 11, 2023 / jaguar health, inc. (nasdaq:jagx) ("jaguar" or the "company") today announced that patient enrollment has surpassed 90% in the company's pivotal phase 3 ontarget clinical trial of crofelemer for prophylaxis of diarrhea in adult cancer patients receiving targeted therapy with or without chemotherapy. "just the week before last - on march 27th - we announced that patient enrollment in ontarget had reached approximately 80%, and we are very happy to report that enrollment in ontarget is now already above 90%," said lisa conte, jaguar's president and ceo.
JAGX Ratings Summary
JAGX Quant Ranking